

September 1, 2025

To Whom It May Concern:

Company SUGI Holdings Co., Ltd.  
Representative: Katsunori Sugiura, Representative Director & President  
(Stock code: 7649, TSE Prime / NSE Premier)  
Inquiries Makoto Kasai,  
Executive Managing Officer, Responsible for  
corporate planning and finance  
(TEL: +81-562-45-2744)

## Notice Regarding the Acquisition of Knock On The Door Inc. as a Subsidiary

SUGI Holdings Co., Ltd. (the “Company”) hereby announces that, as of September 1, 2025, the Company has decided to acquire shares of Knock On The Door Inc. (“Knock On The Door”), hold all its voting rights, and make it a subsidiary of the Company.

### ■ Background and purpose of the acquisition of Knock On The Door as a subsidiary

Striving to contribute to everyone’s healthy, rich lifestyle and serve as the Main Framework Underpinning Local Healthcare, the SUGI Pharmacy Group (the “Group”) operates more than 2,300 stores mainly in the areas of Kanto, Chubu, Kansai, and Hokuriku/Shinshu. Leveraging its strengths in the operation of prescription dispensing drugstores with approximately 5,000 pharmacists and approximately 600 nationally certified dieticians, the Group provides a full lineup of care, covering the range from primary prevention/secondary prevention to medical care/medication and elderly nursing/daily life support, based on the Total Healthcare Strategy.

In addition, in anticipation of market expansion due to the further aging of society and advances in pharmaceutical development, the Group is focusing on home healthcare and support for patients with intractable diseases. In the area of home healthcare, the Group provides home-visit prescription dispensing services to a total of more than 200,000 in-home patients each year. In the field of support for patients with intractable diseases, the Group offers prescription dispensing services specializing in intractable diseases at approximately 150 pharmacies located near university hospitals and other medical institutions across Japan. These efforts not only enhance the Group’s competitive advantage in the medical care and prescription dispensing field but also serve as an important cornerstone for its sustainable growth.

Knock On The Door was founded in 2018 with the philosophy of “Realization of a society where patients with intractable diseases and their families can shine and always stay true to themselves.”

In the areas of intractable and rare diseases such as epilepsy, dementia, and ALS, Knock On The Door collaborates with medical professionals and companies to develop and expand a patient support platform for patients, their families, treatments, and daily lives.

*nanacara*, a smartphone app developed through dialogue with epilepsy patients and their families, allows users to record and share information about epileptic seizures. With the total number of downloads exceeding 37,000, the app has a market share of approximately 33% in the field of pediatric intractable epilepsy. In addition, *nanacara for Doctor*, a cloud-based service that enables medical specialists to provide medical treatment support based on patients’ seizure records, has been introduced to approximately 300 medical institutions nationwide and is used by more than 450 doctors. As indicated by this, the use of the app is expanding in medical settings across the country. These services are highly regarded as advanced solutions that contribute to increasing efficiency in the field of medicine and improving patient satisfaction.

The Company acknowledges the acquisition of Knock On The Door as a subsidiary as an important step in the Group's growth strategy, aiming to establish a "patient-centered care model" by providing more advanced patient support services in the areas of intractable and rare diseases and reinforcing its capabilities related to specialty pharmaceuticals.

Specialty pharmaceuticals refer to medicines developed with advanced technology and used to treat cancer, rare diseases, etc. In recent years, pharmaceutical companies have been accelerating the development of such pharmaceuticals. As shown by the forecast that these pharmaceuticals will account for approximately 60% of all prescription drugs by 2030, they constitute a core area expected to drive growth in the medical care and prescription dispensing field.

By making Knock On The Door a subsidiary, the Group will combine Knock On The Door's expertise and technological base with the Group's store network and prescription dispensing function to promote the following initiatives:

(1) Provision of epilepsy patient support services at the Group's pharmacies

With the number of epilepsy patients in Japan estimated to be approximately 1 million, there is a high level of need for medical treatment and medication support. By providing treatment support services utilizing *nanacara*, used by many patients and medical institutions in the field of epilepsy, at the Group's pharmacies (mainly those located near hospitals), the Group will reinforce its capacity to fill prescriptions for specialty pharmaceuticals in the field of epilepsy.

(2) Expansion to other intractable and rare disease areas

In the specialty pharmaceutical market, which is expected to continue expanding in the future, the Group will leverage epilepsy as a model to expand into other intractable and rare disease areas, such as dementia, ALS, and Parkinson's disease. The Group will work with Knock On The Door to develop new apps and digital services and gradually roll them out using the Group's store and medical networks, thereby striving to expand its share in specialty pharmaceutical prescription dispensing.

(3) Development of new growth areas through the promotion of medical DX

With an eye on the next generation of medical care, the Group will promote the digitalization of medical treatment support and medication management using personal health records (PHRs). By doing so, the Group will help improve the efficiency and quality of medical care while developing new business operations, such as collaboration with pharmaceutical companies to jointly develop and operate patient support programs and cooperation with local governments to support the prevention of severe illness.

Through these initiatives, the Group will accelerate the social implementation of a "patient-centered care model" to help the reinforcement of local medical care networks and the realization of its sustainable growth strategy.

The Group will continue to listen to the voices of patients, their families, and medical professionals as it pursues the ideal medical care and prescription dispensing that society needs.

## ■ Overview of the companies involved

Knock On The Door Inc.

Date of establishment: July 2018

Location: Hilltop Kanda Building, 1-7-6 Kajicho, Chiyoda-ku, Tokyo

Representative: Hiroomi Hayashi, Representative Director

URL: <https://knockonthedoor.jp/>

Business description: Business development and support centered on a support platform for patients and their families

SUGI Holdings Co., Ltd.

Date of establishment: March 1982

Location: 62-1 Shin'e, Yokone-machi, Obu-shi, Aichi

Representative: Katsunori Sugiura, Representative Director and President

URL: <https://www.sugi-hd.co.jp/english/>

Business description: Business management and operation of the entire SUGI Pharmacy Group